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The Design of Potential Anti-Parkinsonian Drugs: What is the 
Dopaminergic Pharmacophore in Ergot Alkaloids? 1 
JOSEPH G. CANNON 
Division of Medicinal and Natural Products Chemistry, College of Pharmacy, 
The University of Iowa, Iowa City, Iowa 52242 
The problem of defining structural similarities between apomorphine and certain ergot alkaloid derivatives, two chemically dissimilar 
types of drugs having similar pharmacological effects, is addressed by considering the three-dimensional geometry of the molecules. 
Conformational analytical concepts can be used to design new chemical entities and to assess structure-activity relationship hypotheses, 
and indeed this strategy has led to synthesis of new categories of potentially clinically valuable agents. 
Some conclusions are presented with respect to the combinations of atoms within the molecules in various chemical categories of 
dopaminergic agonists, which are responsible for the observed pharmacological effects. On the basis of these conclusions, some general 
properties of in vivo dopamine receptors are inferred, and proposals are advanced for structural analysis of the molecule of dopamine itself, 
which may be applicable to the design of new, superior therapeutic agents for those pathological conditions which are referrable to the 
dopaminergic nervous system. 
INDEX DESCRIPTORS: dopaminergic pharmacophore; ergot alkaloids; structure-activity relationships; drug design 
The biochemical involvement of the neurotransmitter substance 
dopamine 1 in the Parkinsonian syndrome is well established, and the 
most successful therapeutic strategy has been the administration of a 
drug (either a biochemical precursor to dopamine itself, or a synthetic 
dopaminergic agonist), for the purpose of stimulating the remaining, 
intact hyperresponsive dopamine receptors in the nigrostriatal path-






Among the agents which have elicited some clinical interest is a 
semi-synthetic derivative of the ergot alkaloid family, a derivative of 
the ergoline ring system, bromocriptine 2. Indeed, dopaminergic 
agonist effects have been noted in a variety of ergoline derivatives: 
lergotrile 3, pergolide 4, and lisuride 5, in addition to bromocriptine. 
It is established that the significant biological effects of these com-
pounds reside in the ergoline ring system, and not in the variety of 
complex substituents on the molecule. In addition to their effects on 
dopaminergic mechanisms, many of the ergolines have a high affiniry 
for a-adrenoceptors and for serotonin receptors. 
Thus, the pharmacologic profile noted for these drugs is the sum total 
of their effects on dopamine receptors, norepinephrine a-receptors, 
and serotonin receptors. It seems probable that any drug derived from 
the ergoline ring system will possess a broad spectrum of side effects. 
Certainly, one of the most important features of any clinically useful 
anti-Parkinsonian agent must be a high degree of pharmacologic 
specificity and freedom from serious side effects. An added complica-
tion is the fact that lergotrile 3 is metabolized to a 13-hydroxy 
metabolite 6 which is exponentially more potent than lergotrile itself 
in several animal assays (2), and which is believed to be responsible for 
the preponderance of the observed dopaminergic effects of the drug. It 
1This work was presented at the College of Pharmacy Centennial Symposium, The 
Uni'letsity of Iowa, Iowa City, September 12-13, 1985. 
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is appealing to propose that lergotrile is a prodrug to its 13-hydroxy 
metabolite. However, not all of the ergot derivatives require this 
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The observed effects of these molecules at serotonin receptors can be 
rationalized. It is apparent that the ergoline system 7 contains an 
indole-3-ethylamine moiety analogous to serotonin 8; thus, the 
ergolines may have an affinity for serotonin receptors because the 




However, rationalization of a close structural similarity between the 
ergoline derivatives and dopamine is not quite as obvious or facile. 
While there is a ~-phenethylamine moiety 10 in the ergoline system 
analogous to that in dopamine (illustrated in structure 9), the ergoline 
system in several very potent dopaminergic molecules lacks the 
catechol di-OH moiety of dopamine (and, indeed, sometimes lacks 
any phenolic groups whatsoever). It is well established that unsub-
stituted ~-phenethylamine 10 is devoid of effects at dopamine 
receptors, and it is this combination of atoms that is contained in most 
of the dopaminergic ergoline derivatives. Therefore, the medicinal 
chemists posed the questions: "What is the dopaminergic phar-
macophore in the ergoline ring system?" To what combination of 
atoms is the affinity of these ergot derivatives for dopamine receptors 
due?" 
Nichols (3) attacked the problem by first noting that the dopamin-
ergically active ergoline derivatives (typified by lergotrile, structure 
11) appear to have the "wrong" absolute configuration at the chiral 
center (position 5) which forms a part of the ~-phenethylamine 
moiety, in comparison with the analogous carbon (6a) in the biologi-
cally active enantiomer, (R)-(-)-apomorphine (structure 12), a prototyp-
12 
!! 
ical dopaminergic agonist, which is frequently used as a reference 
standard drug, for comparison with other dopamine-like synthetic 
agents. 
14 
It is apparent that the hydrogen in the ergoline system is pointed back 
behind the plane of the page, and the equivalent hydrogen in 
apomorphine is projected out in front of the plane of the page. Nichols 
rationalized the pharmacological differences in these absolute configu-
rations upon the premise that the rigidly held pyrrole-3-ethylamine 
moiety of the ergoline ring system (outlined in heavy lines in structure 
13) corresponds to the ~-3,4-dihydroxyphenethylamine moiety with-
in the apomorphine molecule (outlined in heavy lines in structure 14), 
and indeed that this pyrrole ethylamine moiety represents the dopa-
minergic pharmacophore in the ergolines. The emphasized portion of 
the ergoline ring system 13 is biochemically equivalent to the 
emphasized portion of the apomorphine system 14. Nichols drew the 
two ring systems from a different perspective to emphasize these ideas. 
R 
15 16 
\ U N-HO H 
HO 7 
17 
In 15, the ergoline ring system has been turned on its opposite face, 
and it and the apomorphine molecule 16 have been rotated in the 
plane of the page. Priority was placed on correspondence at the chiral 
carbons and the aliphatic ring nitrogen, as shown. The 2,3,4,5,6 
positions of the ergoline system were proposed to correspond to and to 
superimpose upon the 6, 6a, 7, 7a, 8 positions ofapomorphine. Thus, 
the 2- position of the ergolines corresponds to the 8- position of 
apomorphine and to the 8- position of the 2-aminotetralins 17. These 
2-aminotetralins represent a fragment of the apomorphine molecule, 
as well as being congeners of dopamine. They have the same 
2
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stereochemical properties as apomorphine; they have the same molec-
ular shape and, like apomorphine, they are very potent dopaminergic 
agonists. 
Nichols suggested that the C-10 hydroxy of apomorphine is in 
about the same position in space relative to the basic nitrogen as is the 
indole N-H of the ergolines, relative to its basic nitrogen. Analysis of 
molecular models by us did not confirm this: the distance between 
N-6 and the indole ring nitrogen (N-1) in the ergoline ring system 
(structure 18) is approximately 6. 5 A, and the nitrogen-to-C-10 OH 
distance in apomorphine (structure 19) is approximately 7. 8 A. It 
seems to follow from the Nichols proposals that the pyrrole ring N-H 
of the ergolines and the C-10 ("para") OH of apomorphine are 





However, consideration of pharmacological data (4) on the mono-
hydroxylated congeners of apomorphine (structure 20) indicates that 
the 10-monohydroxy molecule is not a direct acting dopaminergic 
agonist, and is not very active/potent. The 9-hydroxy isomer is inert. 
Significant dopaminergic effect is present only in the 11-monohy-
droxy derivative, which does not appear to provide a close superim-
position upon the proposed corresponding region in the ergoline 
system. The Nichols structural correlations are intriguing with 
respect to comparison of chiral centers, but it seems that the structural 
ideas involving interatomic distances are less impressive, in that the 
ergoline structures fit and compare best with structures of inactive 
apomorphine derivatives. 
A test of any structure-activity proposal is its utility in design of 
new agents having the desired biological activity and high potency. 
Kornfeld and co-workers at Eli Lilly and Company accepted the 
hypothesis that in the ergoline class, the rigid pyrrole-3-ethylamine 
moiety rather than the ~-phenethylamine moiety is responsible for 
dopamine agonist properties. To test the hypothesis, they designed 
and synthesized a series of ergoline partial structures (5 ). 
Compound 21 is dopaminergically active, but this structure is a poor 








pyrrole-3-ethylamine and the ~-phenethylamine moieties. Structures 
22 and 23 showed dopamine-like effects, albeit of much lower 
potency than (e.g.) pergolide. These were the first non-benzene 
derived molecules for which significant dopaminergic effect has been 
reported. These results were taken as strong support for the hypothesis 
that the dopaminergic pharmacophore in the ergolines is the pyrrole-
3-ethylamine. These molecules bear n-propyl groups on the basic 
nitrogen. It is an empirical observation, noted first by us and 
subsequently verified many times, that n-propyl groups enhance 
dopaminergic agonist effect, even to the extent of conferring agonist 
effects upon some molecules that were inert or nearly so when they 
bore hydrogen or methyl on the basic nitrogen. 
A detriment to the entire argument is the finding by the Eli Lilly 
group (5) that pyrrole-3-ethylamine 24 is inert in vivo as a dopaminer-
gic agonist. Without experimental evidence, this inactivity was 
rationalized on the basis that this primary amino compound (like 
exogenous dopamine) is rapidly destroyed in vivo by monoamine 
oxidases. The Lilly group did not report preparation or test data for a 
tertiary amine homolog of this pyrrole-3-ethylamine, which would be 
refractory to monoamine oxidases and which should, on the basis of 
their hypothesis, be an active dopaminergic agent. 
In contrast to the Nichols-Lilly ideas, our group at the University 
of Iowa argued that the pharmacophore of ergoline systems is the 
~-phenethylamine moiety, illustrated (structure 25) with lergotrile. 
CH,-CN 
3
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Inspection of molecular models reveals that lergotrile is a rigid system 
and overall, the ring system is planar. Referring to structure 26, if a 
sight be taken down the ethylamine side chain of the 13-phenethyla-
mine moiety within the molecule, with the nitrogen atom (N-6) 
nearest to the eye, the molecule appears as in the Newman projection 
27. The entire indole system of the molecule (heavy lines, structure 
27) is planar and, as drawn, the benzene ring and the pyrrole ring 
project out toward the viewer. The indole ring system is anti to the 
amino nitrogen and, according to our analysis of models, the plane of 
the benzene-pyrrole rings is approximately 20° out of coplanarity with 
the ethylamine side chain. This is an excellent overall approximation 
of what we believe to be one of the biologically significant conformers 
of the flexible dopamine molecule when it interacts with certain of its 
receptors: the so-called a-conformation, shown in structure 28 and 
the Newman projection 29. This is very close to the conformation of 











A significant fact is that the ring nitrogen of indole or pyrrole is not 
basic, but is weakly acidic. Thus, chemically, the N-H in 27 is not 
unlike a phenolic OH, and we have proposed that in these systems, 
this indole ring N-H is bioisosteric with phenol. It occupies the same 
position in space as does the "meta"-OH of dopamine in the biologi-
cally significant a-conformer shown in structure 29. Moreover, our 
past work, as well as that of others, has consistently indicated that the 
"meta"-OH of dopamine is unusually important in the interaction of 
the molecule with its receptors. Interatomic distance measurements 
indicate that the amino-to-meta OH distance in the dopamine 
a-conformer is 6.4 A, and in the lergotrile molecule, the distance 
between the amino N-6 and the indole ring N-H is almost exactly the 
same. Thus, the presence of a biologically potent conformer of the 
dopamine molecule can be visualized within the ergoline structure. 
Reasonable conformations of the ergoline ring fragments 21 and 22 
(with the diagram showing the eye viewing the appropriate aspect of 
the molecule) present the basic amino nitrogen and the indole or 
pyrrole ring nitrogen in the same spatial disposition as the amino 
nitrogen and the "meta"-OH in the a-conformaiton of dopamine, 






In addition, the internitrogen distance in 30 and 31 is approximately 
6.2 A, virtually identical with the N-to-meta OH distance of 6.4 A in 
dopamine. It can be speculated that dopamine receptors cannot 
discriminate between a properly situated indole (or pyrrole) N-H and 
a phenolic OH, which is a classic example of bioisosterism. 
Discussion is pointless, however, unless these ideas can be used to 
design new, potent/active molecules. Our premise, based upon our 
conformational ideas, was that the dopaminergic pharmacophore in 
ergolines is the heavily shaded portion in structure 32, an indole-4-
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Conformational analysis of this indole-4-ethylamine molecule 
shows that the flexible molecule can assume (inter alia) a conformation 
very similar to that of the analogous sequence of atoms in ergoline 
systems such as lergotrile, with the indole ring system coplanar with 
the ethylamine side chain, and projecting out toward the viewer, and 
with the basic nitrogen and the indole ring system anti, as illustrated 
in 34. This simple molecule is very similar to dopamine itself: it is 
flexible like dopamine, and it is capable of existing in a dopamine-like 
a-conformation. 
We synthesized compound 33, bearing n-propyl groups on the 
amino group (6). This is an extremely potent/active dopaminergic 
agonist. Moreover, its pharmacologic effects at dopamine receptors 
qualitatively and quantitatively parallel those of lergotrile and of 
certain other ergolines. However, compound 33 lacks effect at seroto-
nin receptors, and it has only weak actions at adrenergic sites. Thus, 
we have simplified the pharmacology of the ergot-derived 
dopaminergics, and have created a more specific agent with decidedly 
fewer side effects. 
We noted that, like lergotrile, compound 33 exhibits a 25-30 
minute lag period between intravenous administration and produc-
tion of maximal pharmacologic effect (7). Also, the compound, while 
very potent in vivo, showed only extremely weak effects in vitro. In the 
case of lergotrile 3, the lag time observed for onset of effect was 
concluded to be due to metabolic conversion to a 13-hydroxy 
metabolite 6. We speculated that we might be observing similar 
metabolic activation of our indole system, and we designed a molecule 










Compound 35 had a very potent/active dopaminergic agonist profile, 
and the lag time between intravenous administration and maximal 
pharmacologic response was brief. The compound, unlike the non-
oxygenated system 33, was as active in vitro as it was in vivo (7). 
Almost coincident with the communication of our findings on 
these compounds, Boissier and Nedelec at Roussel-Uclaf (France) (9) 
described high dopaminergic potency for a similar system 36. Here, 
the ethylamine side chain of our compound is a part of a piperidine 
ring system. This Roussel compound also appeared to be metabolical-
ly activated in vivo. The Roussel workers concluded that the indole-4-
ethylamine moiety of ergolines is the dopaminergic pharmacophore. 
Interestingly, the absolute configuration of the chiral center in the 
pharmacologically active enantiomer of 36 (as shown) is the same as in 
the analogous position of the biologically active, naturally-derived 
ergolines (9). However, an equivalent chiral center does not exist in 
apomorphine, so that it is not possible to draw structure-activity 
conclusions. It is regrettable that our simple indole-4-ethylamines 
have no asymmetric center for possible assessment of the Nichols ideas 
about stereochemical differences/similarities. Certainly, a weakness of 
our work (and, to a lesser extent, of the Roussel work) is the inability 
of our designed compounds to answer or to address the apparent 
"wrong" stereochemistry between the ergolines and apomorphine. 
And, it must be noted that the Eli Lilly group's argument for the 
pyrrole-3-ethylamine moiety's being the pharmacophoric group of the 
ergolines was weakened by the almost complete inactivity of the 
simple pyrrole-3-ethylamine 24. Both the Lilly-Purdue studies and 
the Roussel-Iowa studies represent reasonable, rational approaches to 
the problem. Both hypotheses about the nature of the dopaminergic 
pharmacophore in ergots seem logical, and both have led to the design 
of dopaminergic agonists having potential clinical utility. However, 
neither hypothesis was adequate to explain pharmacological results on 
all of the compounds studied, and neither hypothesis permitted an 
unequivocal, universally acceptable definition of the dopaminergic 
pharmacophore. Neither hypothesis by itself nor the pharmacologic 
data collected by the proponents of either hypothesis was sufficient to 
permit the construction of a graphic representation of the topography 
of any dopamine receptor. 
The most that we can all agree upon is that significant components 
of the ergoline ring system for dopaminergic agonism seem to be the 
basic nitrogen (capable of bearing a unit positive charge) and the 
indole ring N-H which presumably (like a phenolic OH) can act as a 
facile proton donor for hydrogen bonding with a receptor. Moreover, a 
molecule incorporating these two groups in an appropriate steric 
relationship to each other, with an appropriate inter-nitrogen distance 
(approximately 6.4 A) may demonstate dopamine-like effects. 
I believe that the results of our twenty years of active study of 
dopamine permit us to make some conclusions: Probably many, if not 
most, of the dopaminergic agonist structure-pharmacology correla-
tions that have been made in the past (by us and by others) are naive 
and do not necessarily reflect the true nature of dopaminergic agonist-
receptor interactions, even though we can frequently use these 
correlations rationally to design biologically active compounds. It 
seems increasingly likely that the dopamine receptor protein mole-
cules possess a high degree of flexibility; the protein chain can exist in 
more than one conformation; these conformations are in equilibrium 
with each other and are easily interconvertible. The receptors can alter 
their molecular shapes and the details of their geometry so as to 
compliment and interact with several functional groups in a drug 
molecule. And, depending upon the exact nature of the func-
tionalities in the agonist molecule, the receptor can recognize and 
interact with varying absolute configurations of chiral centers. More-
over, a multiplicity of these different agonist-receptor complexes is 
capable of eliciting a physiological dopaminergic response. Different 
chemical series of dopaminergic agonists may be interacting with the 
same geographic area on the receptor protein molecule but, depend-
ing upon the chemical nature of the specific chemical series of 
agonists, a different conformation of the receptor protein may be 
involved. Thus, within a given chemical series of agonists, there may be a 
well defined structure-activity and stereochemical correlation. But, 
these correlations may disappear when a different chemical series of 
agonists is addressed, and a new combination of structural parameters 
and stereochemical requirements may apply. If this be true, structural 
comparisons and correlations between ergoline derivatives, apomor-
phine derivatives, and other dopaminergic agonist molecular systems 
may not only be meaningless, but actually may be misleading. 
37 
5
Cannon: The Design of Potential Anti-Parkinsonian Drugs: What is the Dopa
Published by UNI ScholarWorks, 1986
174 PROC. IOWA ACAD. SCI. 93(1986) 
As shown in structure 3 7, we view the dopamine molecule as 
comprising three pharmacologically significant structural entities: a 
system of phenolic OH group(s); a ring system; and substitutent(s) on 
the basic nitrogen, in addition to the absolute three-dimensional 
geometry of the molecule . . . the stereochemistry of an asymmetric 
center. Modification of one or more of these four parameters, inde-
pendent of the others, can result in retention, reinforcement, or 
destruction of dopaminergic agonise activity of the molecule. We 
believe that if one parameter (e.g., the phenolic OH groups) is 
modified so as to destroy dopaminergic activity, then one or more of 
the other parameters (e.g., the nitrogen substituents or the absolute 
configuration of an asymmetric center) may be modified at the same 
time, such that the dopaminergic agonise effect will be retained in the 
molecule. This view derives from the concept that the dopamine 
receptors are conformationally highly flexible and can accommodate a 
variety of chemical and stereochemical variations of the dopamine 
molecule. 
If these simple ideas are valid, future structure-activity studies of 
dopaminergic agonises will be infinitely more difficult and challeng-
ing. However, the rewards are vastly improved therapeutic agents, 
not only against the Parkinsonian syndrome, but for treatment of 
some types of schizophrenia, essential hypertension, some kinds of 
cardiac arrhythmias, and perhaps other challenging ailments, will 
make the effort eminently worth doing. 
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